Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
The OptiZest study aims to investigate a personalised dose of Zestril in these patients
Read More
Tag: hypertension
Closed Loop Medicine shares results of proprietary technology for hypertension
CLM-HT01 improved blood pressure and minimised adverse reactions in patients
Read More
Innovation Passport awarded Alnylam and its hypertension therapy
The company received the Innovation Passport in the UK for zilebesiran, an investigational treatment of hypertension
Read More
Scientists to trial world-first long-acting injection for high blood pressure
Long-acting hypertension treatment could provide patients with an injection of medication every six months
Read More
NICE updates hypertension guideline
The clinical management of hypertension accounts for 12% of visits to primary care and up to £2.1 billion of healthcare expenditure.
Read More
J&J announce first-of-its-kind portopulmonary hypertension study results
The findings “Provide important clinical evidence to help inform treatment decisions and fill an unmet need that should benefit patients living with PoPH.”
Read More
Closed Loop secures £2.1m funding
The funding will support the development of a drug and digital approach to treat and manage major health conditions.
Read More
NICE updates high blood pressure guidelines
NICE has published a draft updated guideline on the diagnosis and management of high blood pressure, with thousands more patients to qualify for treatment.
Read More
Immune cell clues offer hope to hypertension patients
Researchers led by the University of Edinburgh have pinpointed cells in the immune system that could be key to tackling high blood pressure.
Read More
J&J shells out $30 billion on Actelion
Johnson & Johnson and Actelion have announced a $30 billion merger that will see the latter’s R&D unit spun out into a separate business, ending months of speculation.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
